Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05685407 · ClinicalTrials.gov registry record · Phase 1
Examining Caffeine as a Treatment for Antidepressant-induced Arousal Dysfunction in Women
A Phase 1 study of Female Sexual Arousal Disorder, sponsored by University of Texas at Austin.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05685407: Completed Phase 1 study of Female Sexual Arousal Disorder, sponsored by University of Texas at Austin.
NCT05685407 is a Phase 1 study of Female Sexual Arousal Disorder that has completed, run by University of Texas at Austin. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05685407, a Phase 1 study of Female Sexual Arousal Disorder, has completed, sponsored by University of Texas at Austin.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Antidepressants have negative effects on genital arousal function that hinder quality of life and jeopardize medication adherence. Moderate sympathetic nervous system (SNS) activation through exercise has shown promising results for improving antidepressant-induced genital arousal dysfunction. It is feasible that caffeine - an SNS stimulant - could improve antidepressant-induced genital arousal difficulties if ingested prior to sex. The goal of the present pilot study is to examine whether the acute administration of 300mg of caffeine increases genital arousal in women experiencing antidepressant-induced genital arousal difficulties. Women will attend two counterbalanced sessions in which they ingest either 300mg caffeine or placebo. Fifteen minutes after ingestion, they will view an erotic film while their heart rate and genital sexual arousal are measured. Caffeine could serve as a low-cost, widely accessible intervention with minimal side effects if efficacy is shown.
Primary Outcome
Vaginal pulse amplitude reflects phasic changes in vaginal engorgement with each heart beat, where higher amplitudes indicate higher levels of blood flow
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Caffeine
Study Locations (1)
Texas
- The University of Texas at Austin, Sexual Psychophysiology Laboratory - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2023-04-15 |
| Phase | Phase 1 |
What the finished NCT05685407 record still lists
NCT05685407 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Female Sexual Arousal Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05685407 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05685407 about?
NCT05685407 is a clinical study titled "Examining Caffeine as a Treatment for Antidepressant-induced Arousal Dysfunction in Women". Antidepressants have negative effects on genital arousal function that hinder quality of life and jeopardize medication adherence. Moderate sympathetic nervous system (SNS) activation through exercise has shown promising results for improving antidepressant-induced genital arousal dysfunction. It is...
What is the current status of trial NCT05685407?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-01-01. Estimated completion is 2023-04-15.
What conditions does trial NCT05685407 study?
This clinical trial studies the following conditions: Female Sexual Arousal Disorder.
What interventions are being tested in trial NCT05685407?
The interventions under investigation include: Placebo (OTHER), Caffeine (DRUG).
Who is sponsoring clinical trial NCT05685407?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05685407 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Female Sexual Arousal Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05685407's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI